Dashboard
Manage Tickers

PSTX Poseida Therapeutics, Inc.

Nasdaq poseida.com


$ -0.06 (-0.63 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.50 $ 4.83 (0.77 %)
DIA $ 477.23 $ 1.80 (0.38 %)
SPY $ 687.11 $ 1.82 (0.27 %)
TLT $ 92.06 $ 0.24 (0.26 %)
GLD $ 363.45 $ -2.63 (-0.72 %)
$ 9.5
-- x --
-- x --
-- - --
$ 1.87 - $ 9.67
21,420,617
na
925.92M
$ 1.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2024 09-30-2024 10-Q
2 08-05-2024 06-30-2024 10-Q
3 05-14-2024 03-31-2024 10-Q
4 03-07-2024 12-31-2023 10-K
5 11-09-2023 09-30-2023 10-Q
6 08-08-2023 06-30-2023 10-Q
7 05-09-2023 03-31-2023 10-Q
8 03-09-2023 12-31-2022 10-K
9 11-10-2022 09-30-2022 10-Q
10 08-11-2022 06-30-2022 10-Q
11 05-12-2022 03-31-2022 10-Q
12 03-10-2022 12-31-2021 10-K
13 11-09-2021 09-30-2021 10-Q
14 08-12-2021 06-30-2021 10-Q
15 05-11-2021 03-31-2021 10-Q
16 03-11-2021 12-31-2020 10-K
17 11-12-2020 09-30-2020 10-Q
18 08-20-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

poseida-therapeutics-highlights-interim-phase-1-results-for-p-bcma-allo1-and-preclinical-data-for-dual-car-t-p-cd19cd20-allo1-at-the-66th-ash-annual-meeting-additional-new-profiling-of-patient-responses-from-the-optimized-lymphodepletion-arm-show-consistent-p-bcma-allo1-cellular-expansion-and-persistence-across-subgroups
Poseida Therapeutics Highlights Interim Ph...
12/09/2024 17:05:46

Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellu...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
11/29/2024 17:35:21

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
11/26/2024 21:06:35

crude-oil-moves-lower-dicks-sporting-goods-earnings-top-views
Crude Oil Moves Lower; Dick's Sporting Goo...
11/26/2024 19:06:45

btig-downgrades-poseida-therapeutics-to-neutral
BTIG Downgrades Poseida Therapeutics to Ne...
11/26/2024 17:05:21

BTIG analyst Justin Zelin downgrades Poseida Therapeutics (NASDAQ:PSTX) from Buy to Neutral.

nasdaq-rises-100-points-abercrombie--fitch-shares-fall-after-q3-results
Nasdaq Rises 100 Points; Abercrombie & Fit...
11/26/2024 17:01:25

william-blair-downgrades-poseida-therapeutics-to-market-perform
William Blair Downgrades Poseida Therapeut...
11/26/2024 16:14:59

William Blair analyst Raju Prasad downgrades Poseida Therapeutics (NASDAQ:PSTX) from Outperform to Market Perform.

us-stocks-mixed-best-buy-posts-downbeat-earnings
US Stocks Mixed; Best Buy Posts Downbeat E...
11/26/2024 14:48:18

hc-wainwright--co-downgrades-poseida-therapeutics-to-neutral-lowers-price-target-to-9
HC Wainwright & Co. Downgrades Poseida The...
11/26/2024 14:13:59

HC Wainwright & Co. analyst Arthur He downgrades Poseida Therapeutics (NASDAQ:PSTX) from Buy to Neutral and lowers the p...

roches-proposed-acquisition-of-poseida-therapeutics-poised-to-establish-new-core-capability-in-cell-therapy-for-cancer-and-autoimmune-diseases-details
Roche's Proposed Acquisition Of Poseida Th...
11/26/2024 14:07:08

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic...

why-poseida-therapeutics-shares-are-trading-higher-by-219-here-are-20-stocks-moving-premarket
Why Poseida Therapeutics Shares Are Tradin...
11/26/2024 10:24:58

best-buy-hp-and-3-stocks-to-watch-heading-into-tuesday
Best Buy, HP And 3 Stocks To Watch Heading...
11/26/2024 07:42:16

Core News & Articles
Poseida Therapeutics To Be Acquired bB Roc...
11/26/2024 06:27:23

Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-trade...

where-poseida-therapeutics-stands-with-analysts
Where Poseida Therapeutics Stands With Ana...
11/15/2024 14:00:18

hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Pose...
11/15/2024 12:21:33

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Pose...
11/08/2024 19:09:51

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

poseida-therapeutics-q3-eps-021-beats-041-estimate-sales-7175m-beat-1627m-estimate
Poseida Therapeutics Q3 EPS $0.21 Beats $(...
11/07/2024 22:27:29

Poseida Therapeutics (NASDAQ:PSTX) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of ...

poseida-therapeutics-to-present-clinical-and-preclinical-data-on-investigational-allogeneic-car-t-cell-therapies-at-sitc-2024-and-ash-2024
Poseida Therapeutics To Present Clinical A...
11/05/2024 21:21:03

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better targe...

hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Pose...
10/30/2024 12:35:38

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

poseida-therapeutics-to-present-new-preclinical-data-supporting-non-viral-gene-editing-with-p-klkb1-101-for-the-treatment-of-hereditary-angioedema
Poseida Therapeutics To Present New Precli...
10/24/2024 12:05:24

Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma & ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION